Title: Money Today-- LegoChem acquired Khanmed... becomes research-based pharmaceutical company

Publication: Money Today/ Dong Hee Kim

Date: 1 October 2015

Summary

• In order to become a research-based pharmaceutical company, LegoChem acquired Khanmed, a medicine distributor.

• LegoChem acquired 20% of the share in July. But due to a positive strategic partnership, they decided to move up the acquisition.

• CEO Yong Zu Kim said “Our vision is to become a research-based pharmaceutical company that has the function to research, produce, sell, and market. The acquisition of Khanmed has set a solid foundation toward our vision."

To view the full article (in Korean), click here ▶

About LegoChem Biosciences

LegoChem Biosciences, Inc. (LCB) is a research-based biotechnology company dedicated to discovering, developing, and commercializing innovative medicines by leveraging our chemistry expertise to make conventional biologics targeted and more potent for the benefit of patients with diseases of high unmet medical needs. We are advancing sustainable pipelines in therapeutic areas in antibiotics, anti-coagulants, oncology, antibody-drug conjugate (ADC), and protein-drug conjugate (PDC).